Pantarhei Bioscience started its activities on January 1, 2001. The company operates as a virtual organisation employing top-executives, who recruit new projects and manage the outsourcing of all activities. (Corporate)

Drug development by Pantarhei Bioscience is characterised by the innovative use of existing compounds. New treatments developed by Pantarhei Bioscience will be safe, address obvious medical needs and have clear medical advantages.Pantarhei Bioscience is specialised in the clinical development of new drugs for the treatment of gender-related diseases. Gender-related Medicine includes diseases and medical treatments that differ in females and males.

Pantarhei has developed a mature clinical pipeline during the first 5-6 years of its existence. (Pipeline)

The Lead project of Pantarhei Bioscience is a new oral contraceptive concept in phase III of clinical development and ready for marketing in 2-3 years.

The Lead compound of Pantarhei Bioscience is estetrol (E4). Estetrol may be suitable for several clinical applications such as:

• the treatment of breast cancer (phase IIA)
• the treatment of prostate cancer (combined phase IB and IIA)
• the treatment of auto-immune diseases (Sjögren’s Syndrome in phase IIA)
• the replacement of ethinylestradiol (EE) in oral contraceptives (phase IIA)
• prevention of osteoporosis (ready to start phase IIB)

Other projects are:

• a method to treat metastasised ovarian cancer
• a natural and orally bioavailable androgen
• a project to diagnose, prevent and treat vaginal HIV transmission (AIDS)

The use of existing compounds i.e. biologicals, hormones and approved drugs or combinations thereof allows fast and cost-effective clinical drug development. The attrition rate is low. (Progress) At present 53 patents and patent applications are in different stages of processing. Preclinical and clinical studies supporting the new treatment concepts are ongoing.

Successfully patented concepts that are supported by clinical data are licensed out to pharmaceutical companies for final clinical development and commercialisation. (Partnering)